8-K current report · filed Aug 25, 2026

Electromed, Inc. (ELMD) 8-K Current Report: August 25, 2026

Item 2.02Item 7.01Item EX-99.3Item EX-99.2Item EX-99.1Item 5.02ELMD overview

Short answer

Electromed, Inc. (ELMD) filed an 8-K current report with the SEC on August 25, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item 5.02 (Departure/Election of Directors or Officers). Press release announces Electromed’s fourth-quarter and fiscal-year 2026 financial results.

Electromed, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces Electromed’s fourth-quarter and fiscal-year 2026 financial results
  • Results cover the fiscal year ended June 30, 2026
  • Detailed financial figures and management commentary are provided in Exhibit 99.1

Item 5.02 · Departure/Election of Directors or Officers

  • CEO James L. Cunniff plans retirement effective on or about April 2, 2027
  • Board beginning comprehensive external search for successor CEO
  • Expected CEO departure also includes resignation from the Board
  • Transition planning creates execution and leadership-continuity risk for investors

Item 7.01 · Regulation FD Disclosure

  • Updated investor presentation signals refreshed messaging for upcoming investor and analyst meetings
  • Press release announces Mr. Cunniff’s planned retirement, creating potential management-transition relevance for shareholders

Item EX-99.1 · Exhibit EX-99.1

  • FY2026 revenue reached a record $73.8M, up 15.3%, led by direct homecare growth of 16.3% to $66.6M
  • Operating income rose 43.7% to $13.9M, with margin expanding to 18.8% from 15.1%, signaling strong operating leverage
  • Net income increased 50.0% to $11.3M, or $1.30 diluted EPS, despite higher sales, marketing, and reimbursement staffing costs
  • Cash rose to $20.5M with no debt, but operating cash flow declined to $9.7M from $11.4M as receivables increased $5.1M
  • $3.9M of share repurchases supported per-share returns while the company invests in sales capacity and bronchiectasis-market expansion

Item EX-99.2 · Exhibit EX-99.2

  • FY26 revenue $73.8M, up from $64.0M, supporting continued double-digit organic growth
  • Operating income $13.9M, up from $9.7M, with margin expanding to 18.8% from 15.1%
  • Gross margin 78.5%, reinforcing the profitability benefit of Electromed’s direct-to-patient model
  • Cash $20.5M and debt $0.0M, providing capacity for growth investments, acquisitions, or shareholder returns
  • Bronchiectasis opportunity estimated at $3.1B in diagnosed patients and $15.1B including undiagnosed prevalence

Item EX-99.3 · Exhibit EX-99.3

  • CEO Jim Cunniff plans retirement on or about April 2, 2027, with concurrent departure from the board
  • National search underway with an executive search firm for his successor
  • Leadership transition follows 15 consecutive quarters of year-over-year revenue and profit growth
  • Key investor risk: execution and strategic continuity during CEO succession at a growth-stage medical device company

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Electromed, Inc. 8-K filings

Get the next ELMD 8-K as it lands

Follow ELMD for push alerts, or ask the research agent what this filing means.